Scancell, (SCLP), a developer of novel immunotherapies for treating cancer and infectious disease, said that it plans to present its ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting over the coming days. 

ModiFY is a first-in-human Phase 1/2 basket trial investigating the use of Modi-1, the first candidate from Scancell's Moditope platform, to treat four different types of cancer: high grade serous ovarian carcinoma, triple negative breast cancer, head and neck squamous cell carcinoma, and renal cell carcinoma.

Scancell told investors that it is currently recruiting patients into the Phase 2a sub-study investigating Modi-1 monotherapy in dose expansion cohorts.

View from Vox

Scancell is a clinical-stage biopharmaceutical company that specialises in immunotherapy in the treatment of cancer and infectious disease. The types of cancer its products treat include pancreatic cancer - the 5th most common cause of cancer death in the UK - alongside small cell lung cancer and ovarian cancer, to name a few. 

The company is building a pipeline of products by utilising its four technology platforms: Moditope and ImmunoBody for vaccines, and GlyMab and AvidiMab for antibodies. 

All four of its products - which are at various stages of preclinical and clinical trials - are immunotherapy treatments for cancer. Immunotherapy uses the immune system to fight cancer, helping the immune system recognise and attack cancer cells. 

In recent years, immunotherapy has come to be seen as a key part of the clinical management of cancer. In a similar way to how vaccines combat diseases, vaccines are made to identify specific proteins found on specific cancer cells. This helps the immune system to recognise and attack those particular cancer cells.

The benefits of using vaccines for immunotherapy in cancer treatment are immense, with very good specificity, low toxicity, and the potential for a durable treatment effect due to immunologic memory.

As Scancell now advances Modi-1 to the next stage of clinical trials, make sure to  to stay up to date with future news and updates.